



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




PRODUCT INFORMATION



Nelfinavir-d₃ Item No. 29416

CAS Registry No.: 1217629-70-3
Formal Name: (3S,4aS,8aS)-N-(*tert*-butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-(methyl-d₃)benzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide
MF: C₃₂H₄₂D₃N₃O₄S
FW: 570.8
Chemical Purity: ≥95% (Nelfinavir)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nelfinavir-d₃ is intended for use as an internal standard for the quantification of nelfinavir (Item No. 15144) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Nelfinavir-d₃ is supplied as a solid. A stock solution may be made by dissolving the nelfinavir-d₃ in the solvent of choice, which should be purged with an inert gas. Nelfinavir-d₃ is slightly soluble in methanol and DMSO.

Description

Nelfinavir is an orally bioavailable inhibitor of the HIV-1 protease ($K_i = 2$ nM).¹ It demonstrates anticancer activity, selectively preventing the growth of HER2-positive breast cancer cells *in vitro* by inhibiting Hsp90 ($IC_{50} = 3.1$ μM).² Formulations containing nelfinavir have been used in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

References

1. Kaldor, S.W., Kalish, V.J., Davies, J.F., II, *et al.* Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. *J. Med. Chem.* **40**(24), 3979-3985 (1997).
2. Shim, J.S., Rao, R., Beebe, K., *et al.* Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. *J. Natl. Cancer Inst.* **104**(20), 1576-1590 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/11/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM